ImmunoGenes is a biotech company with a platform technology that improves the immune response using genetically-modified mice and rabbits that overexpress the neonatal Fc receptor (FcRn). Our IMG-AbS™ patented technology results in a greater number and greater diversity of B cell clones than is typical and a strong immune response against weakly immunogenic targets. This, in turn, generates high-quality monoclonal antibody candidates with high affinity and diversity that pharmaceutical and biotech companies can use in their development of unique therapeutics and diagnostics.
Certain statements contained in these materials are forward-looking statements that involve known and unknown risks, uncertainties, and other factors. ImmunoGenes cannot guarantee that it actually will achieve the plans, intentions or expectations expressed or implied in its forward-looking statements. You should not rely on forward-looking statements as representing the views of ImmunoGenes as of any date subsequent to the date of on which these materials were prepared. The past performance of any ImmunoGenes principal or other person or entity should not be relied upon as an indicator of the future performance of ImmunoGenes.